NIKKEI 225
38,763.40 +527.33 (+1.38%) HANG SENG
18,510.64 -67.66 (-0.36%) CRUDE OIL
78.67 +0.19 (+0.24%) GOLD FUTURES
2,328.10 -3.10 (-0.13%) DOW
38,852.27 +176.59 (+0.46%) Bitcoin GBP
50,643.07 -688.69 (-1.34%)
Elevation Oncology, Inc. (ELEV)
After hours:
- PR Newswire
Elevation Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business Achievements
Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced financial results for the quarter ended March 31, 2024, and highlighted recent business achievements.
- PR Newswire
Elevation Oncology Presents Preclinical Proof-of-Concept Data for HER3-ADC Program at AACR Annual Meeting 2024
Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced new preclinical data demonstrating proof-of-concept for its differentiated HER3-ADC program. The data will be presented in a poster session at the American Association for Cancer Research (AACR) Annual Meeting 2024, being held April 5-10 in San Diego, Ca
- GuruFocus.com
Elevation Oncology Inc (ELEV) Reports Financial Results for Q4 and Full Year 2023
Strategic Advances Amidst Financial Prudence
